# Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

> **NCT02514239** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 43 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** BI 836909

## Key facts

- **NCT ID:** NCT02514239
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-08
- **Primary completion:** 2018-07-17
- **Final completion:** 2020-07-02
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02514239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02514239, "Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02514239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*